Anzeige
Mehr »
Sonntag, 21.12.2025 - Börsentäglich über 12.000 News
Jackpot-News! Q-Gold lässt die "goldene Weihnachts-Katze" aus dem Sack
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DNC4 | ISIN: CA4838092084 | Ticker-Symbol: N/A
1-Jahres-Chart
KANE BIOTECH INC Chart 1 Jahr
5-Tage-Chart
KANE BIOTECH INC 5-Tage-Chart

Aktuelle News zur KANE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKane Biotech Inc.: Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company1
MiKane Biotech Inc.: Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting1
10.12.Kane Biotech Inc.: Kane Biotech Receives Health Canada Approval for revyve Antimicrobial Wound Gel Spray1
KANE BIOTECH Aktie jetzt für 0€ handeln
28.11.Kane Biotech Inc (2): Kane Biotech loses $607,345 in Q3 20251
28.11.Kane Biotech Inc.: Kane Biotech Announces Third Quarter 2025 Financial Results630WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its third quarter 2025 financial results. Third Quarter...
► Artikel lesen
27.11.Kane Biotech Inc (2): Kane Biotech arranges $800,000 private placement1
27.11.Kane Biotech Inc.: Kane Biotech Announces New Private Placement Offering2
04.11.Kane Biotech Inc (2): Kane receives clinical, preclinical data for revyve3
17.09.Kane Biotech Inc (2): Kane Biotech completes submission for wound cleanser1
16.09.Kane Biotech Inc.: Kane Biotech Completes U.S. FDA 510(k) Submission for revyve Antimicrobial Wound Cleanser195WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has completed a U.S. Food and Drug Administration ("FDA")...
► Artikel lesen
11.09.Kane Biotech Inc (2): Kane Biotech enrolls 28 participants for revyve studies2
10.09.Kane Biotech Inc.: Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve Antimicrobial Wound Gel and Spray143WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or "Kane") today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound...
► Artikel lesen
29.08.Kane Biotech reports Q2 results1
28.08.Kane Biotech Inc.: Kane Biotech Announces Second Quarter 2025 Financial Results128WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its second quarter 2025 financial results. Second Quarter...
► Artikel lesen
30.07.Kane Biotech Inc (2): Kane Biotech presents revyve wound care data2
14.07.Kane Biotech Inc.: Kane Biotech to Present at Advanced Wound Care Summit USA1
02.07.Kane Biotech Inc (2): Kane Biotech $1-million debenture private placement1
27.06.Kane Biotech Inc (2): Kane Biotech closes loan conversion1
26.06.Kane Biotech Inc.: Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results1
18.06.Kane Biotech Inc.: Kane Biotech Provides Further Corporate Update183WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Company", "Kane" or "Kane Biotech") provides updates on its reorganizational phase. The Company has terminated...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1